NEW BRUNSWICK, N.J., June 29, 2012 /PRNewswire/ -- GeneAssess, Inc., a New Jersey-based biotechnology company, has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG), Inc., to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging.
According to James M. Golubieski, president of FVCG, the company invested in GeneAssess because the FRY gene appears to be found in the breast cancer model but also shows potential for other cancers.
In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models.
GeneAssess plans to use the investment to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.
"Our findings suggest that FRY could potentially be used as a platform to develop cancer gene-based susceptibility tests, for disease progression and for tumor grading," explained Dr. Helmut Zarbl, founder of GeneAssess and a professor of environmental and occupational medicine at Robert Wood Johnson Medical School. "This tumor suppressor gene could be useful for developing new targeted drugs, especially for the treatment of aggressive and/or advanced breast cancer."
Dr. Zarbl is also a member of the Environmental & Occupational Health Sciences Institute (EOHSI), which is a joint Institute of the University of Medicine and Dentistry of New Jersey and Rutgers University and the Associate Director for Public Health Science at The Cancer Institute of New Jersey.
Dr. Zarbl's research team found that:
|SOURCE Foundation Venture Capital Group, LLC|
Copyright©2012 PR Newswire.
All rights reserved